US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON

0.8390

+0.01601.94%

Post-market: 0.7971-0.0419-4.99%19:57 EDT

Volume:137.41K

Turnover:118.19K

Market Cap:33.84M

PE:-0.54

High:0.9579

Open:0.8640

Low:0.7600

Close:0.8230

Loading ...

Overview Company News Filings

Barinthus Biotherapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Barinthus Biotherapeutics PLC reports results for the quarter ended December 31 - Earnings Summary

Barinthus Biotherapeutics Says As Of December 31, 2024 Cash, Cash Equivalents And Restricted Cash Was $112.4M That Is Expected To Provide Cash Runway Into 2027

Barinthus Biotherapeutics FY 2024 GAAP EPS $(1.55) Beats $(1.67) Estimate, Sales $14.97M Inline

Press Release: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

Calendar of U.S. Earnings Expected in the Week Ahead

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

ACCESS Newswire

Barinthus Biotherapeutics PLC expected to post a loss of 41 cents a share - Earnings Preview

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

ACCESS Newswire

US Exchange Insights: 3 Penny Stocks With Over $40M Market Cap

Simply Wall St.

Barinthus Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

Press Release: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Edesa Biotech And 2 Other Promising US Penny Stocks For Your Radar

Simply Wall St.

Barinthus CSO Nadege Pelletier to depart, Geoffrey Lynn to succeed

Press Release: Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

European Equities Traded in the US as American Depositary Receipts Rising Monday

MT Newswires Live

Barinthus Biotherapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Barinthus Biotherapeutics Reports 'Encouraging' Phase 2b HBV003 Trial Results for Chronic Hepatitis B

MT Newswires Live

Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results

MT Newswires Live

Barinthus announces results from ongoing Phase 2b HBV003 trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BRNS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BRNS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRNS\",,,,,undefined,":{"symbol":"BRNS","market":"US","secType":"STK","nameCN":"BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON","latestPrice":0.839,"timestamp":1745870400000,"preClose":0.823,"halted":0,"volume":137407,"hourTrading":{"tag":"盘后","latestPrice":0.7971,"preClose":0.839,"latestTime":"19:57 EDT","volume":155,"amount":124.469,"timestamp":1745884652990},"delay":0,"floatShares":25979687,"shares":40339395,"eps":-1.55214,"marketStatus":"Closed","change":0.016,"latestTime":"04-28 16:00:00 EDT","open":0.864,"high":0.9579,"low":0.76,"amount":118194.5334088,"amplitude":0.240462,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.55214,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745913600000},"marketStatusCode":5,"adr":0,"adrRate":1,"listingDate":1619755200000,"exchange":"NASDAQ","adjPreClose":0.823,"postHourTrading":{"tag":"盘后","latestPrice":0.7971,"preClose":0.839,"latestTime":"19:57 EDT","volume":155,"amount":124.469,"timestamp":1745884652990},"volumeRatio":8.15346},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRNS\",,,,,undefined,":{"symbol":"BRNS","floatShares":25979687,"roa":"-15.22%","roe":"-38.59%","lyrEps":-1.55214,"volumeRatio":8.15346,"shares":40339395,"dividePrice":0,"high":0.9579,"amplitude":0.240462,"preClose":0.823,"low":0.76,"week52Low":0.64,"pbRate":"0.26","psRate":"2.26","week52High":2.6,"institutionHeld":0,"latestPrice":0.839,"eps":-1.55214,"divideRate":0,"volume":137407,"delay":0,"ttmEps":-1.55214,"open":0.864,"prevYearClose":1.208,"prevWeekClose":0.823,"prevMonthClose":0.9727,"prevQuarterClose":0.9727,"fiveDayClose":0.71,"twentyDayClose":1.05,"sixtyDayClose":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BRNS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521285794","title":"Barinthus Biotherapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2521285794","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521285794?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:31","pubTimestamp":1742560260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BRNS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 08:31 ET (12:31 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2520211454","title":"Barinthus Biotherapeutics PLC reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2520211454","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520211454?lang=en_us&edition=fundamental","pubTime":"2025-03-20 21:32","pubTimestamp":1742477523,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics PLC reports results for the quarter ended December 31 - Earnings SummaryBarinthus Biotherapeutics PLC BRNS.OQ reported a quarterly adjusted loss of 51 cents per share for the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL8N3Q31E0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2520307934","title":"Barinthus Biotherapeutics Says As Of December 31, 2024 Cash, Cash Equivalents And Restricted Cash Was $112.4M That Is Expected To Provide Cash Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2520307934","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520307934?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:28","pubTimestamp":1742470137,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics Says As Of December 31, 2024 Cash, Cash Equivalents And Restricted Cash Was $112.4M That Is Expected To Provide Cash Runway Into 2027","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/03/44413744/barinthus-biotherapeutics-says-as-of-december-31-2024-cash-cash-equivalents-and-restricted-cash-w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS","BK4139"],"gpt_icon":0},{"id":"2520430784","title":"Barinthus Biotherapeutics FY 2024 GAAP EPS $(1.55) Beats $(1.67) Estimate, Sales $14.97M Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2520430784","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520430784?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:27","pubTimestamp":1742470042,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(1.55) per share which beat the analyst consensus estimate of $(1.67) by 7.19 percent. This is a 18.85 percent increase over losses of $(1.91) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44413738/barinthus-biotherapeutics-fy-2024-gaap-eps-1-55-beats-1-67-estimate-sales-14-97m-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Barinthus Biotherapeutics FY 2024 GAAP EPS $(1.55) Beats $(1.67) Estimate, Sales $14.97M Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2520304904","title":"Press Release: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2520304904","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520304904?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:22","pubTimestamp":1742469720,"startTime":"0","endTime":"0","summary":"-- Strategic transformation ongoing, positioning the Company as a focused. -- Highly differentiated, potentially curative immunotherapy for celiac. disease  in the clinic, with first data expected in third. \"Turning to our development candidates designated for partnering, we reported highly encouraging results from two Phase 2 trials in our chronic hepatitis B  program demonstrating that VTP-300 contributed to the achievement of undetectable HBsAg levels in eight participants, with two participants meeting functional cure criteria. Further Phase 2 data are anticipated in the second quarter of 2025, which are expected to strengthen VTP-300's market positioning as a component of a functional cu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","R","BK4139","BRNS"],"gpt_icon":0},{"id":"2520439968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520439968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520439968?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:00","pubTimestamp":1742464800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Amprius Tech Inc                                4Q      (.11)  4:05 PM. ·Lands' End Inc.                                   4Q       .57   6:45 AM. ·Lennar Corp Class A                              1Q      1.70       AMC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRAG","NKE","NKTX","OUST","LEN","DRI","JEF","CBUS","FBRX","DERM","IFRX","MBRX","BRNS","ASO","MGNX","MLKN","RUM","COYA","PL","TELA","SBS","SOWG","SKYE","SPRY","BCAB","BLRX","FLUX","ACRV","THRD","ALUR","CMC","CURV","TITN","BBNX","JKS","GDEV","MNSO","LVTX","MREO","KLC","CDLR","SLS","CELC","TH","LPTX","WOR","RLMD","PAYX"],"gpt_icon":1},{"id":"2520931355","title":"Q1 Virtual Investor Summit: On-Demand Presentations Now Live","url":"https://stock-news.laohu8.com/highlight/detail?id=2520931355","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520931355?lang=en_us&edition=fundamental","pubTime":"2025-03-19 03:30","pubTimestamp":1742326200,"startTime":"0","endTime":"0","summary":"NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors who missed the live sessions can now access company presentations at their convenience.The event, which took place on March 11, featured a diverse lineup of microcap companies showcasing their latest developments, growth plans, and market strategies. With on-demand access, you have the flexibility to revisit key insights and explore potential opportunities to revisit key insights shared during the event.Click the Company Names Below To Access Presentations:. 100% complete response rate  in the most recent U.S. trial results in skin cancer, led by Memorial Sloan Kettering Cancer Center in NY.RI/ROYIF's trifecta strategy combines the upside from the breakout of the silver price to $40-50 to monetize its silverasset for $5-10 million and a potential up to $25 million legal settlement on a co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q1-virtual-investor-summit-demand-193000244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLNN","PYPD","LU0211331839.USD","LU2361044865.SGD","PERF","USJW.SI","UAMY","PRPH","BRNS","MIND","QID","LU1035773651.USD","BK4230","DRTS","DRTSW","IE00BLSP4452.SGD","LU1066051225.USD","LU1917777945.USD","TSYW.SI","ZCARW","FEMY","SQQQ","LU0985320562.USD","LU1585245621.USD","LU1983299246.USD","LU1037948897.HKD","IE00B4R5TH58.HKD","LU1116320901.HKD","LU1934455194.USD","MRK","LU1291159041.SGD","TOVX","ROYIF","IE00BLSP4239.USD","SMMF","ZCAR","CLNNW","LU1066053197.SGD","LU1929549753.HKD","QLD","SG9999014567.USD","VOXR","LU1069347547.HKD","MNQmain","SG9999015358.SGD","SNANF","USAW.SI","TQQQ","NVIW.SI","NQmain","GIFT","SG9999015341.SGD",".IXIC","PSQ"],"gpt_icon":1},{"id":"2519804154","title":"Barinthus Biotherapeutics PLC  expected to post a loss of 41 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519804154","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519804154?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:20","pubTimestamp":1741958406,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics PLC  expected to post a loss of41cents a share - Earnings Preview Barinthus Biotherapeutics PLC BRNS.OQ, BRNS.O is expected to show no change in quarterly revenue when it rep","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX19L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2517577211","title":"Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11","url":"https://stock-news.laohu8.com/highlight/detail?id=2517577211","media":"ACCESS Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517577211?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:30","pubTimestamp":1741267800,"startTime":"0","endTime":"0","summary":"NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.About Barinthus Biotherapeutics plcBarinthus Biotherapeutics  is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome autoimmunity and chronic infectious diseases. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in autoimmunity and infectious diseases, including: VTP-1000, utilizing the SNAP-Tolerance Immunotherapy  platform designed to treat people with celiac disease and VTP-300, that is utilizing the ChAdOx/MVA platform designed as a potential component of a functional cure for chronic HBV infection Fur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/barinthus-biotherapeutics-plc-present-investor-133000766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4211","BRNS","SMMF"],"gpt_icon":0},{"id":"2508683120","title":"US Exchange Insights: 3 Penny Stocks With Over $40M Market Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2508683120","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508683120?lang=en_us&edition=fundamental","pubTime":"2025-02-04 04:05","pubTimestamp":1738613109,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates a landscape marked by tariff uncertainties and fluctuating indices, investors are keenly observing opportunities that may arise in less conventional areas of the market. Penny stocks, while often associated with higher risk, continue to capture attention due to their potential for significant returns when backed by solid fundamentals. In this article, we explore three penny stocks that exhibit financial stability and growth potential, offering investors a chance to uncover value beyond traditional blue-chip investments.Overview: CBAK Energy Technology, Inc. is involved in the manufacturing, commercialization, and distribution of lithium-ion high power rechargeable batteries across Mainland China, the United States, Europe, and other international markets with a market cap of $85.11 million.Click here to discover the nuances of CBAK Energy Technology with our detailed analytical financial health report.Gain insights into CBAK Energy Technology's future","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-exchange-insights-3-penny-200509794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CBAT","BABB","BK4209","BK4096","BK4213","BRNS","IMPP","IMPPP","NRT","PVL"],"gpt_icon":0},{"id":"2503530309","title":"Barinthus Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2503530309","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503530309?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:20","pubTimestamp":1736770800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BRNS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2025 07:20 ET (12:20 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2502686810","title":"Press Release: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2502686810","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502686810?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":"Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update. -- Prioritizing VTP-1000 development in celiac disease, Phase 1 data. -- Postponing further clinical development of VTP-300 in chronic hepatitis B. -- Extending the cash runway to the start of 2027 by reducing costs,including an approximate 65% reduction in workforce and expected closure. -- Future operations will be focused at the U.S. site in Germantown,OXFORD, United Kingdom and GERMANTOWN, Md., Jan. 10, 2025  -- Barinthus Biotherapeutics plc  , today provided a strategic business and financial update. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease.-- The Company will prioritize I&I indications, including antigen-specific. -- The Company plans to extend the cash runway to the start of 2027 by. reducing costs, including a reduction in headcount by approximately 65%. across both si","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRNS","BK4588","BK4533","BK4084","PSA","BK4585","BK4217","CHB"],"gpt_icon":0},{"id":"2492998225","title":"Edesa Biotech And 2 Other Promising US Penny Stocks For Your Radar","url":"https://stock-news.laohu8.com/highlight/detail?id=2492998225","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492998225?lang=en_us&edition=fundamental","pubTime":"2024-12-18 01:08","pubTimestamp":1734455321,"startTime":"0","endTime":"0","summary":"As the Dow Jones Industrial Average experiences a prolonged losing streak and investors closely watch Federal Reserve decisions, market participants are seeking opportunities that might weather such volatility. Penny stocks, though often seen as speculative, can still hold potential when they exhibit strong financial fundamentals. These smaller or newer companies may offer unique value propositions and growth prospects that could appeal to investors looking for under-the-radar opportunities in today's shifting economic landscape.Operations: Edesa Biotech, Inc. currently does not report any revenue segments.Click here to discover the nuances of Edesa Biotech with our detailed analytical financial health report.Assess Edesa Biotech's future earnings estimates with our detailed growth reports.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/edesa-biotech-2-other-promising-170841522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4133","PVL","BK4209","BK4139","SPRU","BK4124","BRNS","BABB","EDSA","BK4213"],"gpt_icon":0},{"id":"2486482068","title":"Barinthus CSO Nadege Pelletier to depart, Geoffrey Lynn to succeed","url":"https://stock-news.laohu8.com/highlight/detail?id=2486482068","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486482068?lang=en_us&edition=fundamental","pubTime":"2024-11-26 05:05","pubTimestamp":1732568721,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics (BRNS) announced the promotion of Geoffrey Lynn to chief scientific officer, or CSO, effective as of December 1. Lynn suc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/barinthus-cso-nadege-pelletier-to-depart-geoffrey-lynn-to-succeed?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/barinthus-cso-nadege-pelletier-to-depart-geoffrey-lynn-to-succeed?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BRNS"],"gpt_icon":0},{"id":"2486467050","title":"Press Release: Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2486467050","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486467050?lang=en_us&edition=fundamental","pubTime":"2024-11-26 05:01","pubTimestamp":1732568460,"startTime":"0","endTime":"0","summary":"OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024  -- Barinthus Biotherapeutics plc  , today announced the promotion of Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer , effective as of December 1, 2024. Dr. Lynn succeeds Nadège Pelletier, Ph.D. who decided to pursue alternative opportunities closer to home after having served as Barinthus Bio's CSO since early 2023. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease.Barinthus Biotherapeutics  is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS","BK4139"],"gpt_icon":1},{"id":"2486103179","title":"European Equities Traded in the US as American Depositary Receipts Rising Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2486103179","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486103179?lang=en_us&edition=fundamental","pubTime":"2024-11-26 00:13","pubTimestamp":1732551208,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were advancing on Monday morning, up 0.5% to 1,324.76 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by semiconductor contract manufacturing company STMicroelectronics  and Spanish bank  Banco Bilbao Vizcaya Argentaria , which rose 5.5% and 2.5%, respectively.They were followed by Spanish bank Banco Santander , which added 2.3%.The decliners from continental Europe were led by Swedish food company Oatly  and Norwegian energy company Equinor , which fell 1.1% and 0.8%, respectively.From the UK and Ireland, the gainers were led by clinical-stage biopharmaceutical company Barinthus Biotherapeutics  and biotech Compass Pathways , which rose 5.1% and 4.1%, respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Amarin  and clinical-stage cell therapy company TC Biopharm , which were each shedding 2.2%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4212","STM","SAN","BBVA","BK4521","OTLY","TCBP","SAN.AU","AMRN","BK4539","BK7142","AFG","BK4207","IE00BMPRXN33.USD","BK4588","EQNR","STM.AU","LU2308191902.HKD","BK4107","IE00BMPRXR70.SGD","BK4117","BK4585","BRNS","BK4139","BK7095","BK4141","BK4554","BK4201","BK4548","CMPS"],"gpt_icon":1},{"id":"2484918834","title":"Barinthus Biotherapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2484918834","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484918834?lang=en_us&edition=fundamental","pubTime":"2024-11-19 17:39","pubTimestamp":1732009140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BRNS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2024 04:39 ET (09:39 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRNS"],"gpt_icon":0},{"id":"2483848300","title":"Barinthus Biotherapeutics Reports 'Encouraging' Phase 2b HBV003 Trial Results for Chronic Hepatitis B","url":"https://stock-news.laohu8.com/highlight/detail?id=2483848300","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483848300?lang=en_us&edition=fundamental","pubTime":"2024-11-16 01:29","pubTimestamp":1731691788,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics  on Friday reported \"encouraging\" results from its ongoing phase 2b HBV003 trial for chronic hepatitis B.The study, involving 121 participants, assessed VTP-300 in combination with a low dose of anti-PD1 antibody nivolumab, and new data shows eight participants achieved complete HBsAg loss, while two met the criteria for a functional cure, the clinical-stage biopharmaceutical company said.Barinthus said the ongoing study data shows that stronger responses could occur in patients treated with the VTP-300 and nivolumab. Preliminary safety data also showed that the treatment was well-tolerated, with no treatment-related serious adverse events reported as of the data cutoff, the company said.Shares of Barinthus Biotherapeutics were down more than 16% in recent Friday trading.Price: 1.12, Change: -0.26, Percent Change: -18.84","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRNS","BK4139"],"gpt_icon":0},{"id":"2483307755","title":"Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483307755","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483307755?lang=en_us&edition=fundamental","pubTime":"2024-11-16 01:27","pubTimestamp":1731691643,"startTime":"0","endTime":"0","summary":"Arbutus Biopharma  said Friday new data from phase 2a trial of imdusiran followed by Barinthus Biotherapeutics'  VTP-300 plus a low dose of nivolumab in chronic hepatitis B patients showed \"promising\" results.The preliminary data showed that trial participants who received the regimen experienced increased rates of HBsAg loss compared with those who received imdusiran and VTP-300 or placebo.The data were presented at the Liver Meeting 2024 of the American Association for the Study of Liver Diseases.Arbutus shares were down 2% in recent trading, while those of Barinthus slid nearly 19%.Price: 3.56, Change: -0.07, Percent Change: -2.07","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABUS","BK4139","BRNS"],"gpt_icon":0},{"id":"2483092993","title":"Barinthus announces results from ongoing Phase 2b HBV003 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2483092993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483092993?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:15","pubTimestamp":1731687327,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics (BRNS) announced “the most significant data so far” from the ongoing Phase 2b HBV003 clinical trial. The data will be pre...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/barinthus-announces-results-from-ongoing-phase-2b-hbv003-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/barinthus-announces-results-from-ongoing-phase-2b-hbv003-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BRNS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRNS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-20","symbol":"BRNS","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2024-11-06","symbol":"BRNS","fiscalQuarterEnding":"2024/09","expectedEps":-0.45,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"pre","actualEps":-0.21},{"market":"US","date":"2024-08-08","symbol":"BRNS","fiscalQuarterEnding":"2024/06","expectedEps":-0.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":-0.43},{"market":"US","date":"2024-05-13","symbol":"BRNS","fiscalQuarterEnding":"2024/03","expectedEps":-0.64,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"pre","actualEps":-0.4},{"market":"US","date":"2024-03-20","symbol":"BRNS","fiscalQuarterEnding":"2023/12","expectedEps":-0.55,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1710907200000,"reportTimeType":"pre","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRNS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRNS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1701489600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BRNS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BRNS","date":"2025-04-25","current":-0.538968,"percent":0.953353,"low":-2.280697,"twenty":-1.373547,"median":-0.828027,"eighty":-0.702626,"high":-0.44914,"avg":-1.02124,"sd":0.375328,"marketCap":32916946},"quantilePoints":[{"date":"2023-11-10","current":-2.280697,"twenty":-2.227364,"median":-2.147364,"eighty":-2.067364,"marketCap":125276430},{"date":"2023-11-17","current":-1.472853,"twenty":-1.912639,"median":-1.482838,"eighty":-1.444894,"marketCap":113767552},{"date":"2023-11-22","current":-1.35802,"twenty":-1.608463,"median":-1.465364,"eighty":-1.380987,"marketCap":104897539},{"date":"2023-12-01","current":-1.425372,"twenty":-1.531387,"median":-1.472853,"eighty":-1.406949,"marketCap":110099995},{"date":"2023-12-08","current":-1.545247,"twenty":-1.548243,"median":-1.492824,"eighty":-1.422886,"marketCap":119359516},{"date":"2023-12-15","current":-1.502809,"twenty":-1.545746,"median":-1.507071,"eighty":-1.435398,"marketCap":116081468},{"date":"2023-12-22","current":-1.667569,"twenty":-1.629624,"median":-1.518886,"eighty":-1.45388,"marketCap":128808008},{"date":"2023-12-29","current":-1.818598,"twenty":-1.661578,"median":-1.524178,"eighty":-1.463866,"marketCap":140474003},{"date":"2024-01-05","current":-1.822343,"twenty":-1.722489,"median":-1.530269,"eighty":-1.472853,"marketCap":140763242},{"date":"2024-01-12","current":-1.657583,"twenty":-1.757438,"median":-1.547743,"eighty":-1.472853,"marketCap":128036703},{"date":"2024-01-19","current":-1.647598,"twenty":-1.741461,"median":-1.572707,"eighty":-1.480841,"marketCap":127265397},{"date":"2024-01-26","current":-1.452882,"twenty":-1.725485,"median":-1.553984,"eighty":-1.480841,"marketCap":112224941},{"date":"2024-02-02","current":-1.352528,"twenty":-1.722489,"median":-1.532765,"eighty":-1.451873,"marketCap":104473321},{"date":"2024-02-09","current":-1.271197,"twenty":-1.706512,"median":-1.523479,"eighty":-1.406949,"marketCap":98191039},{"date":"2024-02-16","current":-1.238844,"twenty":-1.682547,"median":-1.517787,"eighty":-1.357411,"marketCap":95692009},{"date":"2024-02-23","current":-1.338049,"twenty":-1.677554,"median":-1.516789,"eighty":-1.341045,"marketCap":103354928},{"date":"2024-03-01","current":-1.41294,"twenty":-1.674558,"median":-1.50494,"eighty":-1.343042,"marketCap":109139719},{"date":"2024-03-08","current":-1.323071,"twenty":-1.669566,"median":-1.502809,"eighty":-1.343042,"marketCap":102197970},{"date":"2024-03-15","current":-1.253173,"twenty":-1.661577,"median":-1.472853,"eighty":-1.328064,"marketCap":96798832},{"date":"2024-03-22","current":-1.269731,"twenty":-1.654588,"median":-1.472853,"eighty":-1.301103,"marketCap":93130931},{"date":"2024-03-28","current":-1.236403,"twenty":-1.650594,"median":-1.452882,"eighty":-1.295112,"marketCap":90686423},{"date":"2024-04-05","current":-1.947467,"twenty":-1.650594,"median":-1.45036,"eighty":-1.291729,"marketCap":142840848},{"date":"2024-04-12","current":-1.767048,"twenty":-1.675557,"median":-1.472853,"eighty":-1.295112,"marketCap":129607635},{"date":"2024-04-19","current":-1.438048,"twenty":-1.670564,"median":-1.455378,"eighty":-1.298107,"marketCap":105476484},{"date":"2024-04-26","current":-1.288883,"twenty":-1.667031,"median":-1.438048,"eighty":-1.298107,"marketCap":94535731},{"date":"2024-05-03","current":-1.138233,"twenty":-1.662768,"median":-1.419156,"eighty":-1.291729,"marketCap":83485999},{"date":"2024-05-10","current":-1.247016,"twenty":-1.655586,"median":-1.407947,"eighty":-1.280564,"marketCap":91464848},{"date":"2024-05-17","current":-1.338523,"twenty":-1.650594,"median":-1.395374,"eighty":-1.278423,"marketCap":94574653},{"date":"2024-05-24","current":-1.248513,"twenty":-1.643604,"median":-1.379677,"eighty":-1.275322,"marketCap":88214937},{"date":"2024-05-31","current":-1.104879,"twenty":-1.635615,"median":-1.37437,"eighty":-1.270728,"marketCap":78066316},{"date":"2024-06-07","current":-1.046873,"twenty":-1.621636,"median":-1.366121,"eighty":-1.261117,"marketCap":73967834},{"date":"2024-06-14","current":-1.055159,"twenty":-1.597671,"median":-1.356497,"eighty":-1.253173,"marketCap":74553331},{"date":"2024-06-21","current":-0.690549,"twenty":-1.5777,"median":-1.352836,"eighty":-1.245382,"marketCap":48791447},{"date":"2024-06-28","current":-0.765129,"twenty":-1.570211,"median":-1.350281,"eighty":-1.236891,"marketCap":54060923},{"date":"2024-07-05","current":-0.789988,"twenty":-1.560225,"median":-1.343042,"eighty":-1.220891,"marketCap":55817415},{"date":"2024-07-12","current":-0.812086,"twenty":-1.547743,"median":-1.338523,"eighty":-1.203246,"marketCap":57378742},{"date":"2024-07-15","current":-0.834183,"twenty":-1.547244,"median":-1.338286,"eighty":-1.19142,"marketCap":58940068},{"date":"2024-08-02","current":-0.841641,"twenty":-1.546745,"median":-1.338049,"eighty":-1.17902,"marketCap":59467016},{"date":"2024-08-09","current":-0.844428,"twenty":-1.544819,"median":-1.331919,"eighty":-1.144779,"marketCap":53861854},{"date":"2024-08-16","current":-0.803496,"twenty":-1.539612,"median":-1.328064,"eighty":-1.092435,"marketCap":51250963},{"date":"2024-08-23","current":-0.772414,"twenty":-1.530768,"median":-1.322286,"eighty":-1.051845,"marketCap":49268402},{"date":"2024-08-30","current":-0.790952,"twenty":-1.527773,"median":-1.3031,"eighty":-1.045215,"marketCap":50450844},{"date":"2024-09-06","current":-0.760055,"twenty":-1.527054,"median":-1.298107,"eighty":-0.902686,"marketCap":48480108},{"date":"2024-09-13","current":-0.790952,"twenty":-1.523898,"median":-1.293812,"eighty":-0.829258,"marketCap":50450844},{"date":"2024-09-20","current":-0.756965,"twenty":-1.522221,"median":-1.290805,"eighty":-0.813197,"marketCap":48283034},{"date":"2024-09-27","current":-0.741517,"twenty":-1.519545,"median":-1.287184,"eighty":-0.79711,"marketCap":47297666},{"date":"2024-10-04","current":-0.766234,"twenty":-1.517727,"median":-1.278854,"eighty":-0.791312,"marketCap":48874255},{"date":"2024-10-11","current":-0.735276,"twenty":-1.517348,"median":-1.275766,"eighty":-0.790181,"marketCap":46899577},{"date":"2024-10-18","current":-0.741517,"twenty":-1.51599,"median":-1.271197,"eighty":-0.788177,"marketCap":47297666},{"date":"2024-10-25","current":-0.883641,"twenty":-1.511649,"median":-1.26959,"eighty":-0.788177,"marketCap":56363052},{"date":"2024-10-31","current":-0.883641,"twenty":-1.507071,"median":-1.261798,"eighty":-0.789436,"marketCap":56363052},{"date":"2024-11-08","current":-1.00297,"twenty":-1.502809,"median":-1.253173,"eighty":-0.789988,"marketCap":57998763},{"date":"2024-11-15","current":-0.960023,"twenty":-1.502809,"median":-1.24843,"eighty":-0.789988,"marketCap":55515269},{"date":"2024-11-22","current":-0.687502,"twenty":-1.482838,"median":-1.238844,"eighty":-0.784772,"marketCap":39756173},{"date":"2024-11-29","current":-0.685791,"twenty":-1.47485,"median":-1.235499,"eighty":-0.783536,"marketCap":39657211},{"date":"2024-12-06","current":-0.646972,"twenty":-1.472853,"median":-1.217885,"eighty":-0.773215,"marketCap":37412464},{"date":"2024-12-13","current":-0.570449,"twenty":-1.472853,"median":-1.204564,"eighty":-0.772414,"marketCap":32987333},{"date":"2024-12-20","current":-0.709582,"twenty":-1.472853,"median":-1.180594,"eighty":-0.767891,"marketCap":41033025},{"date":"2024-12-27","current":-0.737409,"twenty":-1.463866,"median":-1.162113,"eighty":-0.767891,"marketCap":42642163},{"date":"2025-01-03","current":-0.86263,"twenty":-1.455877,"median":-1.146416,"eighty":-0.766897,"marketCap":49883285},{"date":"2025-01-10","current":-0.793063,"twenty":-1.451873,"median":-1.104879,"eighty":-0.767891,"marketCap":45860439},{"date":"2025-01-17","current":-0.702626,"twenty":-1.445881,"median":-1.087822,"eighty":-0.76515,"marketCap":40630740},{"date":"2025-01-24","current":-0.751323,"twenty":-1.438048,"median":-1.055159,"eighty":-0.760055,"marketCap":43446732},{"date":"2025-01-31","current":-0.695669,"twenty":-1.437904,"median":-1.049635,"eighty":-0.751323,"marketCap":40228456},{"date":"2025-02-07","current":-0.695669,"twenty":-1.425372,"median":-1.046873,"eighty":-0.741517,"marketCap":40228456},{"date":"2025-02-14","current":-0.719983,"twenty":-1.41294,"median":-1.010409,"eighty":-0.741517,"marketCap":41634440},{"date":"2025-02-21","current":-0.733931,"twenty":-1.41294,"median":-0.988453,"eighty":-0.741517,"marketCap":42441021},{"date":"2025-02-28","current":-0.674799,"twenty":-1.408946,"median":-0.960023,"eighty":-0.737409,"marketCap":39021602},{"date":"2025-03-07","current":-0.709513,"twenty":-1.403161,"median":-0.92717,"eighty":-0.735338,"marketCap":41029002},{"date":"2025-03-14","current":-0.737409,"twenty":-1.400759,"median":-0.908358,"eighty":-0.735007,"marketCap":42642163},{"date":"2025-03-21","current":-0.665373,"twenty":-1.392324,"median":-0.894425,"eighty":-0.729208,"marketCap":40637009},{"date":"2025-03-28","current":-0.693525,"twenty":-1.384445,"median":-0.883641,"eighty":-0.723496,"marketCap":42356364},{"date":"2025-04-04","current":-0.50198,"twenty":-1.380338,"median":-0.866957,"eighty":-0.719294,"marketCap":30657940},{"date":"2025-04-11","current":-0.452443,"twenty":-1.378328,"median":-0.844428,"eighty":-0.715148,"marketCap":27632485},{"date":"2025-04-17","current":-0.465653,"twenty":-1.375818,"median":-0.840368,"eighty":-0.709554,"marketCap":28439273},{"date":"2025-04-25","current":-0.538968,"twenty":-1.373547,"median":-0.828027,"eighty":-0.702626,"marketCap":32916946}],"updateTime":1745884925186}}}